الفهرس 
cover EnglishOnly 14 pages are availabe for public view
 |  | from | 217 |  |  |
| | | from | 217 | | |
Abstract
Title: Risk-Adapted Chemotherapy in Advanced-StageHodgkin’s Lymphoma. Background and Aim of the Work: Hodgkin’s Lymphoma is an uncommon malignant tumor of the lymphatic systemrepresents about 10% of all Lymphomas, one of the first cancers to be cured by combination chemotherapy. A prospective study to test the efficacy of the German regimen BEACOPP baseline in the treatment of the advanced stage poor risk Hodgkin’s lymphoma and to compare the results with the ABVD regimen as regard response, survival and toxicity. Patients and Methods: This is a prospective phase II randomized trial that has been conducted on 60 cases with advanced-stage Hodgkin’s Lymphoma ,The patients were randomized into two arms, 30 patients in each arm, Arm A: received ABVD regimen, Arm B: received BEACOPP(base-line)regimen for 6-8 cycles in each arm. All patients were subjected to close follow-up to assess the response to treatment and possible complications. Results: Median age of the patients at time of diagnosis in arm A was 43 years, and in arm B was 39 years,In the treatment Arm A (ABVD), complete response (CR) was achieved in 18 cases (60%), partial response (PR) was achieved in 8 cases (26.7%), stationary response was achieved in two cases (6.7%) and PD (progressive disease) in two cases (6.7%). In the treatment Arm B (BEACOPP), complete response (CR) was achieved in 20 cases (66.7%), partial response (PR) was achieved in 6 cases (20%), stationary response was achieved in two cases (6.7%) and PD (progressive disease) in two cases (6.7%). As regard the response after 8 cycles in both treatment arms, our study found that there was no significant difference between patients achieved CR versus patients did not achieve CR in both treatment arms with P= 0.6. In Arm A (ABVD), the mean progression free survival (PFS) was 29.9 months while in Arm B (BEACOPP), the mean PFS was 32.5 months with no statistically significant difference (P=0.57). In Arm A (ABVD), the mean disease free survival (DFS) was 29.4 months while in Arm B (BEACOPP), the mean DFS was 30.4 months with no statistically significant difference (P=0.87). Conclusion: There was no significant difference between ABVD arm and base-line BEACOPP arm as regard the response rate and survival after finishing the 8th cycle of chemotherapy. Key words:Hodgkin’s Lymphoma –Advanced-Stage – ABVD – BEACOPP – Response – Survival.